NCT00765011已完成2 期
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello17 个研究点 分布在 1 个国家目标入组 94 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 94
- 试验地点
- 17
- 主要终点
- Specific survival free of total laryngectomy
研究概览
简要总结
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy.
详细描述
This study is being sponsored by a cooperative medical group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form.
- •Men or women, age (18 and 70).
- •ECOG scale:0-
- •Life expectancy superior to 3 months.
- •Larynx squamous carcinoma histologically demonstrated.
- •Patients with larynx squamous carcinoma, stage III-IVA, with resectable disease whose surgery will imply a total laryngectomy. The T should be a T3, T4A, or a T2 not candidate for a partial laryngectomy. In case of T2 of any of both locations it will be required a III or IVA stadium.
- •Patients to be able to receive treatment with TPF followed by normofractionated radiotherapy with cetuximab.
- •Measurable disease (OMS criteria).
- •Neutrophils superior or equal to 1500/mm3, platelets superior or equal to 150.000/mm3, hemoglobin superior or equal to 10 g/dl.
- •Adequate renal function: creatinin lower or equal to 120 µmol/l (1,4mg/dl)
- •Adequate hepatic function: bilirubin lower or equal to 1 x UNL, AST and ALT lower or equal to 2,5 UNL, alkaline phosphatase lower or equal to 5 UNL.
- •Seric calcium adjusted to albumine lower or equal to 1,25 UNL.
- •Adequate nutritional condition: loss of weight <20% with relation to the theoretical weight and albumin superior or equal to 35 g/L.
- •Use of an effective contraceptive method.
排除标准
- •Metastatic disease
- •Surgical treatment, previous radiotherapy and/or chemotherapy for the study disease.
- •Other tumour locations in H&N that are not larynx.
- •Other stages that are not III or IVa without metastasis and resectable disease.
- •The following cases, which will be considered candidates for radical surgery, will not be included in the study:
- •Tumors of the subglottis.
- •Tumors of glottis or supraglottis with subglottal extension
- •Tumor that destroys the thyroid cartilage and/or cricoid and it extends to thyroid gland or soft necks's tissues.
- •Tumor of supraglottis with a superior extension to 1 cm towards the tongue base (the extension will be measured since the vallecula).
- •Other previous and/or synchronic squamous carcinoma.
- •Diagnosis of another neoplasia in the last 5 years, excepting carcinoma in situ of uterine neck and/or a cutaneous carcinoma basocellular properly treated.
- •Active infection(at needs endovenous antibiotics), including active tuberculosis and diagnosed HIV.
- •Not controlled hypertension defined as arterial systolic tension superior or equal to 180 mm Hg and/or diastolic arterial tension superior or equal to 130 mm Hg baseline.
- •Pregnancy or breastfeeding.
- •Immunity systemic treatment, chronic and concomitant, or hormonal treatment of the cancer.
- •Other antineoplasic concomitant treatments.
- •Coronary clinically significant arteriopathy or precedents of myocardial infarction in the last 12 months or high risk of not controlled arrhythmia or cardiac not controlled insufficiency.
- •Pulmonary obstructive chronic disease that had needed 3 or more hospitalizations in the last 12 months.
- •Active non controlled peptic ulcer.
- •Presence of a psychological or medical disease that could prevent to accomplish the study by the patient or to grant his/her signature in the informed consent form.
- •Known drugs abuse (excepting excessive consumption of alcohol).
- •Known allergic reaction to some of the components of the treatment of the study.
- •Previous treatment with monoclonal antibodies or other transduction of the sign inhibitors or treatment directed against the EGFR.
- •Any experimental treatment in 30 days before entry in the study.
研究组 & 干预措施
Group A
Experimental
TPF plus concomitant treatment with cetuximab and conventional radiotherapy
干预措施: TPF, radiotherapy and cetuximab (Drug)
Grupo B
Other
Surgery
干预措施: H&N surgery (Procedure)
结局指标
主要结局
Specific survival free of total laryngectomy
时间窗: Three years after the end of treatment with radiotherapy and cetuximab
Time from the start of TPF treatment to death caused by the disease or by the treatment of the disease, or even to surgery involving total laryngectomy. Deaths caused by other reasons were considered "censored" data on the date of death.
次要结局
未报告次要终点
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLCNon Small Cell Lung Cancer (NSCLC)NCT00492206University of Pittsburgh40
已完成
2 期
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic CancerPancreatic CancerNCT00225784Dartmouth-Hitchcock Medical Center37
终止
2 期
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8KRAS Protein VariantPathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8NCT04106362Jonsson Comprehensive Cancer Center1
已完成
1 期
Chemoradiation Treatment for Head and Neck CancerHead and Neck CancerNCT00704639Trans Tasman Radiation Oncology Group60
已完成
2 期
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck CancerCancerNCT00703976University of Pittsburgh80